Investigation of gemcitabine plus lomustine treatment in mice with transplantable lymphosarcoma LIO-1
Stukov, A.N.; Tarasenkova, A.A.; Gershanovich, M.L.; Filatova, L.V.; Semiglazova, T.I.; Latipova, D.K.; Vershinina, S.F.
Voprosy Onkologii 57(2): 221-224
2011
ISSN/ISBN: 0507-3758 PMID: 21809669 Document Number: 652076
Efficiency of gemcitabine plus lomustine treatment of transplantable lymphosarcoma LIO-1 in mice was significantly higher than that of monotherapy. According to the area under the kinetic curve for tumor growth, antitumor action, for single maximum tolerable dose of gemcitabine 25 mg/kg body, rose 4.6 times (p < or = 0.001), for lomustine 50 mg/kg body,--2.9 times (p < or = 0.01). The combination involved moderately increased toxicity. Lethality rate for gemcitabine+lomustine, 50 mg/kg body each, was as low as one and a half times as compared with gemcitabine therapy alone, 50 mg/kg body, (30 and 20%, respectively). The antitumor action of the combination (50 mg/kg body), was 32 times that of gemcitabine 50 mg/kg body (p < or = 0.001) and lomustine 50 mg/kg body--30 times (p < or = 0.001).